medwireNews: Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.
Eva Svehlikova (Medical University of Graz, Austria) and colleagues tested the novel insulin – AT278, which comes at a concentration of 500 U/mL – in 38 men with type 1 diabetes of an average 19 years’ duration during an 8-hour euglycemic clamp.
When AT278 was compared with standard insulin aspart U100, both at a total dose of 0.3 U/kg, AT278 had a significantly faster onset and maximum exposure was reached earlier. This translated to a more rapid glucose-lowering effect, with onset of action in a median of 11.5 versus 21.5 minutes for AT278 versus aspart U100.
Insulin exposure was fourfold higher during the first 30 minutes after administration of AT278 versus aspart U100, giving a twofold larger glucose-lowering effect within the first 60 minutes, Svehlikova told delegates at the ATTD meeting in Barcelona, Spain.
Over the entire duration of the clamp, the insulin exposure and glucose-lowering efficacy of AT278 was noninferior to insulin aspart U100.
Svehlikova noted that, besides providing a smaller injection volume so that people with high insulin needs do not need to split their injections, concentrated insulins also facilitate the development of smaller injection devices.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group